In the years after Kalydeco (ivakaftor) became available, the use of pancreatic enzyme replacement therapy (PERT) fell among…
Articles by Marisa Wexler, MS
Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) significantly reduced rates of colonization with the bacterium Pseudomonas aeruginosa in adults with cystic…
Compounds secreted by Lactobacillus, a group of bacteria commonly used in probiotics, are able to impede the growth of Pseudomonas…
Intellia Therapeutics and ReCode Therapeutics are joining forces to develop new genomic medicines for people with cystic…
The frequent use of aminoglycosides — a class of antibiotics commonly used to help treat lung infections in people with…
A new triple-combination CFTR modulator therapy for cystic fibrosis (CF) — vanzacaftor, tezacaftor and deutivacaftor —…
Enterprise Therapeutics has raised £26 million (nearly $33 million USD) in series B financing, which the company is planning…
Treatment with SPI-1005 in adults with cystic fibrosis (CF) appeared to lessen the risk of ear damage related…
The eighth annual BreatheCon, a virtual event hosted by the Cystic Fibrosis Foundation that brings together adults with…
Results of three global clinical trials of a new triple-combination CFTR modulator therapy for cystic fibrosis (CF) —  vanzacaftor,…